Treatment of Bronchial Asthma (Zeequn Nafas) with Unani Medicine
- Conditions
- Health Condition 1: J989- Respiratory disorder, unspecified
- Registration Number
- CTRI/2023/01/048733
- Lead Sponsor
- Central Council for Research in Unani Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
(1) Patients of Bronchial Asthama for atleast 6 months having following symptoms: wheeze, Shortness of Breath, Chest Tightness and cough that vary over time and in intensity, Expiratory airflow limitation as suggested by a decreased FEV1.
(2) Objective evidence for reversible airway obstruction (>=12% and >=200 mL change in FEV1 and/or a 25% and 60 L/min change in PEFR) either spontaneously or after treatment.
(3) patients with Asthma Control Questionnaire Score >1.5
The patients of Zeeq-un-Nafas (Bronchial Asthma) with following conditions will be excluded from the study:
1. Patients below 18 years and above 65 years of age., 2. Pregnant and lactating mother
3. FEV1/FVC ratio < 50%
4. Patient with other Respiratory Tract Infections, tuberculosis and malignancy.
5. Patients with Presence of chronic cough with expectoration for 2-3 months in each of 2 successive years.
6. Patient with co-morbidities, Diabetes Mellitus, Hepatic, Renal Insufficiency and Heart disease .
7. Patients with Tobacco Smoking.
8. Patient with regular use of oral or systemic corticosteroids for conditions other than Asthma.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in ACQ score, Pulmonary function test in cases of Zeeq un NafasTimepoint: 17 DAYS
- Secondary Outcome Measures
Name Time Method Haematological and biochemical assessment for safety assessmentTimepoint: At baseline and after 51 days